UnitedHealth not sold on fecal DNA testing for CRC screening; Exact Sciences slips 1%

|By:, SA News Editor

Exact Sciences (EXAS -1.3%) was down as much as 3% earlier in the session on the news that insurer UnitedHealth (UNH +0.7%) will not cover its Cologuard colorectal cancer (CRC) screening test saying fecal DNA testing for CRC screening/monitoring is "unproven and not medically necessary." The non-coverage ruling went into effect April 1.

Source: Bloomberg